Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis

…, KP Kim, SC Kim, SS Kim, AH Ko… - JNCI: Journal of the …, 2019 - academic.oup.com
Background FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients.
The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable …

Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology

…, J Hardacre, WG Hawkins, K Klute, AH Ko… - Journal of the National …, 2021 - jnccn.org
Pancreatic cancer is the fourth leading cause of cancer-related death among men and women
in the United States. A major challenge in treatment remains patients’ advanced disease …

[HTML][HTML] Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer

…, S Motoyama, A Lièvre, H Uronis… - … England Journal of …, 2021 - Mass Medical Soc
Background No adjuvant treatment has been established for patients who remain at high
risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or …

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

…, J Weinkle, GE Kim, L Jakkula, HS Feiler, AH Ko… - Nature medicine, 2011 - nature.com
Pancreatic ductal adenocarcinoma (PDA) is a lethal disease. Overall survival is typically 6
months from diagnosis 1. Numerous phase 3 trials of agents effective in other malignancies …

Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical …

…, A Ohtsu, K Shitara, R Geva, J Bleeker, AH Ko… - JAMA …, 2018 - jamanetwork.com
Importance Therapeutic options are needed for patients with advanced gastric cancer whose
disease has progressed after 2 or more lines of therapy. Objective To evaluate the safety …

Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology

…, MP Malafa, M Al-Hawary, H Asbun… - Journal of the National …, 2017 - jnccn.org
Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality
multiphase imaging can help to preoperatively distinguish between patients eligible for …

[HTML][HTML] Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?

EJ Walker, AH Ko - World journal of gastroenterology: WJG, 2014 - ncbi.nlm.nih.gov
While an increasing number of therapeutic options are now available for the first-line treatment
of locally advanced or metastatic pancreatic cancer, the optimal choice for treatment in …

Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE …

…, C Caglevic, L Villanueva, E Goekkurt, H Satake… - JAMA …, 2020 - jamanetwork.com
… Dr Ko reported grants from Merck during the conduct of the study; grants from Roche/Genentech,
Merrimack, Celgene, Bristol-Myers Squibb, Apexigen, Abgenomics, Astellas, and …

[HTML][HTML] Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 …

…, EM O'Reilly, RA Wolff, ZA Wainberg, AH Ko… - Nature medicine, 2022 - nature.com
Chemotherapy combined with immunotherapy has improved the treatment of certain solid
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). …

Cavitary pulmonary lesions in patients infected with human immunodeficiency virus

JE Gallant, AH Ko - Clinical Infectious Diseases, 1996 - academic.oup.com
The differential diagnosis of cavitary pulmonary lesions in individuals infected with human
immunodeficiency virus (HIV) is broad, especially in patients with advanced disease. In …